Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 181 clinical trials
featured
A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®

A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and

  • 538 views
  • 23 Nov, 2020
  • 1 location
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore

vorinostat
bexarotene
systemic therapy
electron beam therapy
platelet count
  • 3 views
  • 29 Jan, 2021
  • 1 location
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be

bexarotene
neutrophil count
treatment regimen
lymphoma
mycosis
  • 112 views
  • 08 Nov, 2020
  • 1 location
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 …

mycosis
lymphoma
  • 0 views
  • 07 Nov, 2020
  • 1 location
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

cyclophosphamide
peripheral t-cell lymphoma
etoposide
ct scan
prednisone
  • 3 views
  • 21 Jan, 2021
  • 1 location
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical

  • 5 views
  • 22 Jan, 2021
  • 1 location
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

patients with untreated natural killer(NK)/T cell lymphoma

  • 9 views
  • 07 Nov, 2020
  • 1 location
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

  • 2 views
  • 21 Jan, 2021
  • 1 location
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma

  • 1 views
  • 23 Jan, 2021
  • 1 location
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell

  • 0 views
  • 24 Jan, 2021
  • 1 location